Ono enters discovery agreement with Xention
This article was originally published in Scrip
Executive Summary
Japan's Ono Pharmaceutical has entered an agreement with Xention for the discovery of novel small molecules targeting ion channels. The private UK firm will receive an up-front payment and milestones, as well as research funding for the initial two-year term of the programme.